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amining predictors of medication class prescribed. RESULTS: There were 4,916
individuals in the study (1,788 in DA cohort, 646 in MAO-B, and 2,482 in LD). Results
of the logistic regression revealed that older patients were significantly less likely
to receive DA (OR0.977; 95% CI 0.966-0.988) or a MAO-B (OR0.968; 95% CI0.954-
0.983), compared to LD. Compared to LD cohort, patients who receive a MAO-B were
significantly less likely to be diagnosed with pre-period depression (OR0.540; 95%
CI 0.310-0.940) and patients who received a MAO-B or DA were significantly less
likely to be diagnosed with psychoses (MAO-B - OR0.220; 95% CI 0.105-0.459: DA –
OR0.732; 95% CI 0.542-0.989). Furthermore, results revealed that patients diag-
nosed by a neurologist were significantly more likely to receive a DA (OR1.651;
95% CI 1.353-2.014) or a MAO-B (OR1.607; 95% CI 1.193 – 2.165), compared to LD.
Region of residence and health plan membership were also found to predict initial
medication class. CONCLUSIONS: These analyses indicate that patient character-
istics, health status, diagnosing physician and access disparities all impact initial
therapeutic class of medication prescribed for patients with PD.
PND72
ACCESS, UPTAKE AND UTILIZATION MANAGEMENT OF MULTIPLE SCLEROSIS
PRODUCTS IN THE UNITED STATES
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: During 2007-2011 Multiple Sclerosis (MS) was the only category that
experienced triple digit growth in sales, leading to doubling of their sales from $3.4
billion in 2007 to $7 billion in 2011. This has led to change in payer coverage and
utilization of branded MS products. This study was undertaken to understand
current trends in sales, access and utilization management for MS products in the
United States. METHODS: Sales data for MS branded products was analyzed using
IMS Health 2007-2011 data. Access and utilization management trends were ana-
lyzed using preferred drug list and coverage policies of top US health plans. Primary
discussions were conducted with pharmacy and medical directors to understand
new trends in coverage of MS products. RESULTS: More than half (approximately
59%) of the branded MS products are covered by health plans as non-preferred
products or at Tier 3/4 . Significant majority (84%) of these products were covered
with prior authorization or pre-certification criteria. Quantity limits were used by
34% of the plans. Use of step therapy or progression prescription is not currently
common and was found in only 5% of the plans. In this sample (n37), only one
plan ( 5%) had formulary exclusion for an MS product. Payer designated specialty
pharmacies are increasingly being used by various health plans. Compared to 2007,
payer coverage of MS products shows significant increase in use of PA (40% in 2007
versus 84% in 2012). Payers express high concern for rapidly growing MS category
and report use of more utilization management approaches to control spending.
CONCLUSIONS: MS products are facing more aggressive utilization management.
Patient access for new MS therapies could be limited due to non-preferred status,
high co-pay or strict PA criteria.
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OBJECTIVES: To map the health care utilization of multiple sclerosis (MS) patients
incl. MS-specific drug therapy in the ambulatory setting of the Statutory Health
Insurance (SHI) system in Bavaria/Germany. METHODS: Pseudonymised adminis-
trative claims data of the SHI-accredited physicians in Bavaria/Germany (April 2005
– December 2009) were used. Patients with at least one MS diagnosis (ICD-10 G35)
documented by a neurologist or psychiatrist or at least one disease modifying drug
(DMD) prescription (interferon beta-1(a/b), glatirameracetat, or natalizumab). All
cases of outpatient medical services with an MS diagnosis were considered. Anal-
ysis of MS-associated drug therapy included DMD, drugs used for symptomatic
relief and systemic corticosteroids for relapse therapy. Persistence (duration of
continuous prescription) and medication possession ratio (MPR; percentage of days
covered by medication) were calculated for DMD. RESULTS: The annual number of
MS patients ranged from n12.800 (2005) to n18.200 (2009). The proportion of
patients with at least one DMD prescription (interferon beta, glatirameracetat, na-
talizumab, azathioprin) increased from 46% (2005) to 51% (2009). The average per-
sistence for these drugs (excl. natalizumab) varied between 12 months (glatiram-
eracetat) and 14 months (interferons). The median MPR varied between 0,69
(natalizumab) and 0,84 (interferon beta 1-a) in the first year following the index
prescription. Mostly, these drugs were prescribed by neurologists. In total, 10,060
patients receiving systemic corticosteroids for the therapy of relapse were identi-
fied between 2005 and 2009. The average number of such therapies per year and
patient was about 1.5. The percentage of patients with relevant MRI scans (neuro-
cranium / spinal cord) was substantial higher in patients with relapse therapies
compared with patients without such therapy. CONCLUSIONS: The analysis indi-
cated (1) an increase of disease prevalence but also of patients supplied with DMD
between 2005 and 2009 and (2) the importance of neurologists within the MS treat-
ment.
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OBJECTIVES: To identify and explore how reimbursement decisions for natali-
zumab, a treatment for multiple sclerosis (MS), were overturned from an initial
rejection to a recommendation. METHODS: This analysis was conducted in con-
juntion with a wider review of the global reimbursement landscape for MS thera-
pies. We reviewed reimbursement decisions or recommendations from global
payer decision-making agencies, including any decisions where an initial rejection
was overturned. We reviewed the agency rationale for both the original and sub-
sequent decisions, and how the manufacturer influenced the decision reversal.
RESULTS: Since 2006, 17 payer decisions for natalizumab were identified (six rec-
ommendations, eight restricted recommendations and three rejections). The three
rejected decisions were later overturned by the manufacturer submitting further
evidence. To PBAC this involved re-defining the indirect comparison to consider
the heterogeneity in the trials included. To SMC and CADTH post-hoc analysis was
submitted for the specific subgroup of rapidly evolving severe relapsing remitting
MS. For CADTH a 15% price discount was agreed in addition. Across all agencies
clinical need was an important factor. CONCLUSIONS: By emphasising unmet
needs, submitting further evidence in defined subgroups and ensuring indirect
comparisons are methodologically sound, it has been possible to overturn initial
negative decisions by payer agencies to restricted recommendations in define sub-
group. Identification of the optimum treatable population has proved pivotal in the
reversal of fortune.
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OBJECTIVES: There is conflicting evidence in published literature regarding the
association between montelukast and neuropsychiatric disturbances. We sought
to determine if the use of montelukast was associated with neuropsychiatric dis-
turbances in children with Asthma.METHODS:A 10% sample of the LifeLink health
plan claims data was used to identify subjects less than 18 years of age with a
primary diagnosis of asthma between Jan 1, 1998 and Dec 31, 2009. Multiple case
definitions for neuropsychiatric disturbances were formulated ranging from nar-
row to broad measures based on the diagnoses of neuropsychiatric related disor-
ders or use of a psychotropic medication. We used a nested case control design and
each case was matched to 3 controls on age, gender and geographic region and
controls were assigned an index date based on the matched case. Exposure to
montelukast was measured as any exposure during the year, recency of exposure,
cumulative duration of exposure and cumulative dose of exposure during the 30
days and 365 days prior to the outcome. Conditional logistic regression was used to
estimate the unadjusted and the adjusted odds ratios after controlling for
confounders. RESULTS: Using the broadest definition for neuropsychiatric distur-
bances, 1,920 cases and 5,760 matching controls were identified. Cases were more
likely to be diagnosed with epilepsy, diabetes, cancer and hypothyroidism, and
were more likely to use inhaled corticosteroids, long-acting beta2-agonists, sys-
temic corticosteroids and metoclopramide. Subjects exposed to montelukast dur-
ing the year had an unadjusted OR of 1.085 (CI 0.962 – 1.223) and an adjusted OR of
1.032 (CI 0.909 – 1.172) for experiencing a neuropsychiatric disturbance. None of the
other montelukast exposure measures showed a positive association except a cu-
mulative dose of exposure between 351mg and 900mg (OR1.308; CI: 1.082 – 1.581).
CONCLUSIONS: Preliminary results do not suggest a consistent positive associa-
tion between montelukast and neuropsychiatric disturbances.
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OBJECTIVES: COPD is an important cause of morbidity and mortality. Statistics
Korea presented in 2009 the mortality of COPD was 9.4 per one hundred thousand
marking the disease as one of the 10 major death causes in Korea. This study was
performed to investigate epidemiologic data especially incidence and risk factors
associated with COPD exacerbations in Korea.METHODS: A retrospective observa-
tional study was carried out on 1,112 COPD patients from 47 medical centers
throughout Korea. The data collection was performed at enrollment and a past year
from the enrollment. The COPD patients were defined by GOLD criteria 2010. Also
we investigated demographic characteristics, COPD exacerbation, Lung function
Test, Comorbidity, COPD assessment test (CAT), and COPD medication. RESULTS:
Among 1,112 patients, more than half of the respondents were more than 70 years
old, 91% (n1,011) were male, mean BMI was 22.2 (SD 3.3) kg/m2, mean COPD
duration was 5.8 years, and 55.5% (n616) were classified as chronic bronchitis. The
occurrence of exacerbation was 35.4% (n394), the mean frequency of exacerba-
tion in past year was 0.67 (SD1.28), and decrease of FEV1/FVC results align with
GOLD stage was statistically significant (p0.0001). The most frequently reported
comorbidities were hypertension (36.0%, n400) and bronchial asthma (16.6%,
n185). Mean CAT sum score was 16.8 (SD 8.3). The most frequently used COPD
medication was long-acting muscarinic antagonist (47.9%). Multivariate logistic
regression results show the effect on exacerbation in the subjects who had only
pulmonary emphysema was 0.7 times than the subjects who had only chronic
bronchitis (95%CI [0.49-0.96], p-value0.001), and subjects with history of pneumo-
nia were 11.1 times higher than in the subjects without history of pneumonia (95%
CI [6.89-17.87], p-value0.0001). CONCLUSIONS: Our results suggested that the
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